Withings drops its flagship scale price by more than half, launching the BodyFit at $280 for users of GLP‑1 drugs. The model mirrors the high‑end Body Scan’s design, featuring a tension‑reel grab handle and a single‑lead ECG. Users hold the bar at waist height to trigger a bioelectrical impedance test that maps six‑segment body composition for daily monitoring in real‑time.

BodyFit targets the 30 million Americans on GLP‑1 agonists, who often lose muscle while shedding fat. The scale passes a small current through the body, yielding 98 % accuracy for muscle mass and 99 % for fat mass, matching DEXA scans from Mon Stade. Users receive coaching via the Withings app, offering weight goals, calorie balance, and muscle‑preservation tips in the long term today.

Withings markets BodyFit as a clinically accurate, mid‑range alternative to its $600 flagship. By focusing on muscle preservation for a growing GLP‑1 cohort, the company taps a niche that balances affordability and precision. The device is now available through Withings’ store, with other retailers slated to carry it soon, making advanced body analytics more accessible for everyday users now today.